Anti-inflammatory cytokine secretion in LPS-stimulated THP-1 macrophages

Anti-inflammatory cytokine secretion in LPS-stimulated THP-1 macrophages is a phenotypic assay rather than a single molecular target. This experimental model utilizes the THP-1 human monocytic cell line, which is differentiated into macrophage-like cells and subsequently stimulated with Lipopolysaccharide (LPS) to trigger an inflammatory response via Toll-like receptor 4 (TLR4) signaling (Tsuchiya et al., 1980; Poltorak et al., 1998). The assay measures the production of anti-inflammatory mediators, such as Interleukin-10 (IL-10), to evaluate the immunomodulatory effects of potential therapeutic compounds (Moore et al., 2001). While it is a standard tool in drug discovery for identifying anti-inflammatory agents, it represents a complex biological process involving multiple signaling pathways, including NF-κB and MAPK, rather than a discrete protein or receptor. Consequently, it is classified as a functional readout for screening and efficacy monitoring in inflammatory disease research. This system allows for the assessment of how drugs might shift the immune profile from a pro-inflammatory to an anti-inflammatory state in a human-derived cellular context.

Other names

THP-1 cytokine release assayLPS-induced THP-1 activationMacrophage anti-inflammatory response model

Not applicable as this is a phenotypic readout; however, drugs tested in this system typically act by modulating TLR4 signaling, NF-κB activation, or MAPK pathways to alter the balance of cytokine production.